Email Updates

You are here

AVAC's Blog: P-Values

  • TAG and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high-level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

    November 10, 2020
    AVAC
  • HIV prevention advocates following COVID-19 vaccines got not one but two pieces of scientific news in the past two days—both as welcome as the US election results announced over the weekend. The HIV Prevention Trials Network announced that injectable long-acting cabotegravir (CAB-LA) provided high levels of protection among cisgender women at risk of HIV; and Pfizer announced high levels of protection in its COVID-19 vaccine candidate.

    November 10, 2020
    General
    AVAC
  • Over the weekend, we at AVAC and allies around the world witnessed history and gained hope as the results of the American presidential election (finally) got announced. News also came in that the HPTN 084 trial of injectable long-acting cabotegravir for HIV prevention in cisgender women found a high level of effectiveness at a scheduled interim data review.

    November 9, 2020
    AVAC
  • AVAC enthusiastically welcomes the news that another trial of the long-acting, injectable antiretroviral cabotegravir (CAB-LA) for HIV prevention for HIV pre-exposure prophylaxis (PrEP) has demonstrated safety and efficacy, this time among cisgender women.

    November 9, 2020
    AVAC
  • While we celebrate the historic election of Joe Biden and Kamala Harris as the next President and Vice President of the United States, we also acknowledge the enormous public health and global development challenges that incoming Administration must address.

    November 8, 2020
    AVAC
  • More than nine months into this new pandemic, we know that COVID-19 continues to have an enormous negative impact on many global health priorities, including HIV, TB, malaria and routine vaccine programs, as well as reproductive health. But these outcomes are not a foregone conclusion. We can already see how civil society, communities, and countries are developing and implementing innovative ways to combat COVID-19 without losing ground in other areas.

    October 20, 2020
    Amref Health Africa
    AVAC
    Friends of the Global Fight
  • Updates to AVAC’s Global PrEP Tracker are in for Q3 2020, showing that overall global uptake continued to climb even in the midst of COVID-19. The number of people who have started on PrEP has reached 773,474, an increase of more than 23 percent since the year began. This figure includes countries where the burden of HIV is high, such as Kenya and South Africa, and despite the impact of COVID-19 on healthcare systems.

    October 14, 2020
    AVAC
  • Developing COVID-19 vaccines at “pandemic speed” depends on an unprecedented global research effort and on innovative strategies to shorten the vaccine testing and distribution timeline. Speed is important, but not at the expense of ethics, safety, robust engagement, equitable access and scientific rigor.

    October 14, 2020
    Mitchell Warren
  • The latest estimates for COVID-19 anticipate a death toll approaching 2.8 million by year’s end. Global health leaders of every stripe struggle to sustain the gains against HIV, TB, malaria, other preventable diseases and unintended pregnancies. Advocates must be armed with information and tools to demand transparency, and to get effective interventions for both HIV and COVID-19 developed and distributed equitably. Read on for recently produced resources to help get the job done.

    September 24, 2020
    General, Microbicides
    AVAC
  • COVID-19 has devastated communities and health systems around the world – but it has also created an historic global effort leading to the unprecedented development of more than 165 potential vaccines against COVID-19. Equally impressive innovations are speeding vaccine testing within a rigorous scientific framework, while manufacturing and transportation capacity are being scaled up to distribute millions of doses of future COVID vaccines to those who need them most.

    September 24, 2020
    General
    Uché Blackstock
    Mitchell Warren

Pages